Home/Pipeline/Glioblastoma Moonshot

Glioblastoma Moonshot

Glioblastoma

ResearchOpen Project

Key Facts

Indication

Glioblastoma

Phase

Research

Status

Open Project

Company

Owkin

About Owkin

Founded in 2016 by an oncologist and a machine learning pioneer, Owkin is building an agentic AI infrastructure for biology, aiming to automate R&D and connect research directly to patient care. Its core platform, K Pro, is an AI agent designed to generate and validate therapeutic hypotheses using real-world patient data. The company is well-funded, has commercialized CE-marked diagnostics, and collaborates with a vast network of academic and pharmaceutical partners to advance precision medicine.

View full company profile

Therapeutic Areas

Oncology Glioblastoma Colorectal Cancer Breast Cancer

Other Glioblastoma Drugs

Drug	Company	Phase	Status
Ropidoxuridine (IPdR)	Shuttle Pharmaceuticals	Phase 2	Active
LNTH-2505	Lantheus Medical Imaging	Preclinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
OPC-001 (PDC Candidate)	Oncopeptides	Phase 1/Window-of-Opportunity	Active (Fast-Track Designation)
αvβ3-targeted ADC	Xintela	Preclinical	Lead Optimization
Undisclosed	Biossil	Phase 2/3	Active
GLIX1	Hemispherian	Phase 1	Active
InC01	InCephalo Therapeutics	Pre-clinical	Active
Glioblastoma Combination Therapy	JLP Health	Pre-clinical	Active
ENV105	Kairos Pharma	IND Cleared	Active
LMP744	Gibson Oncology	Phase 2	Active
BEA-17	Beactica Therapeutics	Pre-clinical	Active